Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06790784 · ClinicalTrials.gov registry record · Phase 3
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
A Phase 3 study of Proliferative Diabetic Retinopathy (PDR), sponsored by Jaeb Center for Health Research.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
- 20
- Study locations
NCT06790784: Recruiting Phase 3 study of Proliferative Diabetic Retinopathy (PDR), sponsored by Jaeb Center for Health Research.
NCT06790784 is a Phase 3 study of Proliferative Diabetic Retinopathy (PDR) that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 426 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06790784, a Phase 3 study of Proliferative Diabetic Retinopathy (PDR), is actively recruiting participants, sponsored by Jaeb Center for Health Research.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.
Primary Outcome
Visual acuity is measured as a continuous integer letter score from 0 to 100, with higher numbers indicating better visual acuity. A letter score of 85 is approximately 20/20 and a letter score of 70 is approximately 20/40.
Conditions Studied
Interventions
- DRUG Faricimab
- PROCEDURE Vitrectomy
- DEVICE Endolaser
- DEVICE Panretinal Photocoagulation (PRP)
Study Locations (20)
Florida
- Florida Retina Consultants - Lakeland
- Ophthalmic Partners of Florida, PA dba Central Florida Retina - Orlando
- Retina Associates of Florida, LLC - Tampa
California
- Retina Associates of Southern California - Huntington Beach
- Loma Linda University - Loma Linda
Massachusetts
- Boston Medical Center Corporation - Boston
- Joslin Diabetes Center - Boston
Texas
- Retina Consultants of Texas, PA - Bellaire
- Texas Retina Associates - Lubbock
Georgia
- Southeast Retina Center, P.C. - Augusta
Illinois
- Illinois Retina Associates SC Oak Park Site - Oak Park
Indiana
- Midwest Eye Institute - Carmel
Iowa
- Wolfe Clinic, P.C.- West Des Moines - West Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2025-08-04 |
| Est. Completion | 2031-08 |
| Phase | Phase 3 |
What NCT06790784 shows while recruiting
NCT06790784 is an interventional study that assigns participants to a tested intervention. The registered 426 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Proliferative Diabetic Retinopathy (PDR) appearing as the primary indexed condition, and to 4 interventions - of which Faricimab is the first listed.
NCT06790784 names 20 study sites across 15 states, led by Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06790784 about?
NCT06790784 is a clinical study titled "Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR". This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as...
What is the current status of trial NCT06790784?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2025-08-04. Estimated completion is 2031-08.
What conditions does trial NCT06790784 study?
This clinical trial studies the following conditions: Proliferative Diabetic Retinopathy (PDR).
What interventions are being tested in trial NCT06790784?
The interventions under investigation include: Faricimab (DRUG), Vitrectomy (PROCEDURE), Endolaser (DEVICE), Panretinal Photocoagulation (PRP) (DEVICE).
Who is sponsoring clinical trial NCT06790784?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06790784 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proliferative Diabetic Retinopathy (PDR)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06790784's enrollment target sits among peer trials
426 883rd of 2000 higher than 1,118 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
- NCT05340738 · 425 participants · NA
AI-Based Fidelity Feedback to Enhance CBT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI